Drug Database
AN

anti-D immunoglobulin

✓ Approved

Kedrion · Polyclonal Antibodies · Polyclonal Antibodies

What is anti-D immunoglobulin?

anti-D immunoglobulin is a polyclonal antibodies developed by Kedrion. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyKedrion
Drug ClassPolyclonal Antibodies, Cell-based Therapies, Antibody
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Kedrion

Therapeutic Indications

anti-D immunoglobulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersRhesus haemolytic disease of newborn✓ Approved

Related Research Articles

PubMedJournal of Alzheimer's disease : JAD2026-10-16

Immunoglobulin GM (γ marker) allotypes as potential genetic markers of efficacy of lecanemab therapy in Alzheimer's disease.

Pandey Janardan P JP

Lecanemab is a humanized IgG1 monoclonal antibody that targets amyloid-β (Aβ) aggregates, a pathological hallmark of Alzheimer's disease (AD). In the largest clinical trial of its kind to date, lecanemab slowed cognitive decline by 27% in patients with early-stage AD. Lecanemab has also been shown to reduce cerebral Aβ deposition. Lecanemab expresses the immunoglobulin GM 3 allotype, which is defined by an arginine residue in the CH1 region of the γ1 chain and is potentially immunogenic in individuals who lack this allotype. I hypothesize that anti-GM 3 antibodies, generated either following lecanemab administration or acquired previously through maternal-fetal incompatibility or transfusion of allotype-incompatible blood products, may form immune complexes with the therapeutic antibody. These immune complexes could be cleared by phagocytic cells, including microglia, thereby reducing the availability and efficacy of lecanemab and contributing to therapeutic nonresponsiveness. If validated, GM allotypes could serve as genetic markers for predicting response to lecanemab therapy and may help guide personalized treatment strategies in AD.

PMID 42885677
Read full article →
PubMedBiology2026-10-16

Casein Hydrolysate Peptides Attenuate Immunosenescence and Inflammaging in a D-Galactose-Induced Mouse Model of Aging.

Cui Mengni M, Xu Zheng Z, Cheng Jianbo J, Zhang Jikun J et al.

Aging populations worldwide face increasing burdens from physiological deterioration. Bioactive peptides derived from milk proteins have attracted interest for their biological activities, yet systematic evidence against aging remains limited. Here, we investigated casein hydrolysates in a D-galactose-induced murine aging model. Following eight weeks of oral administration at graded doses, we quantified systemic oxidative stress markers, inflammatory cytokine profiles, hepatic and cerebral histopathology, and multiple immune competence parameters. Our data demonstrate that casein peptides dose-dependently suppressed lipid peroxidation, elevated endogenous antioxidant enzyme activities, and rebalanced cytokine networks toward an anti-inflammatory state. Concurrently, peptide treatment attenuated tissue lesions in both liver and brain, while restoring thymus and spleen indices, normalizing T-cell subset distributions, and recovering serum immunoglobulin levels. These findings indicate that oral administration of the casein hydrolysate peptide preparation was associated with improvements in redox homeostasis, inflammatory status, tissue integrity, and immune function in D-galactose-induced aging mice. This work provides mechanistic insights into casein peptides as a multi-target protective agent against age-associated physiological decline, supporting further exploration of their therapeutic potential in aging biology.

PMID 42883414
Read full article →
PubMedmSphere2026-10-16

Characterization of the Peromyscus leucopus immunoglobulin germline repertoire and anti-OspA antibody response reveals conserved germline IGHV features among cricetid rodents.

Zhou Yu Y, Telford Sam R SR, Buchthal Joanna J, Esvelt Kevin K et al.

Peromyscus leucopus (P. leucopus) is an important reservoir host for several zoonoses, including Borrelia burgdorferi (B. burgdorferi), the causative agent of Lyme disease. However, the immunoglobulin germline repertoire underlying antibody responses in this reservoir host remains poorly defined. In this study, we characterized the immunoglobulin variable genes of P. leucopus and identified 12 IGHV, 12 IGKV, and 3 IGLV gene families comprising 129, 87, and 12 genes, respectively. These genes exhibited similar usage patterns to those of Mus musculus (M. musculus). We also identified a high-divergence region (HDR) within the germline IGHV loci of three Borrelia sp.-susceptible Cricetidae species, P. leucopus, Peromyscus maniculatus (P. maniculatus), and Arvicola amphibius (A. amphibius). Compared with the corresponding regions in Muridae species, the Cricetidae HDRs are expanded and contain a large number of IGHV genes. To investigate the antigen-specific features of the repertoire, we analyzed the antibody responses of P. leucopus to B. burgdorferi outer surface protein A (OspA), a highly immunogenic tick midgut adhesin involved in midgut colonization. Comparative analysis of more than 140 IGHV genes from immunized P. leucopus showed that germline IGHV genes encoding anti-OspA antibodies exhibited higher sequence similarity to corresponding germline IGHV genes in P. maniculatus and A. amphibius than did P. leucopus germline IGHV genes not associated with anti-OspA responses.IMPORTANCEThis study characterized the immunoglobulin gene repertoire of Peromyscus leucopus and revealed extensive diversity across its variable-region loci. Analysis of antibody response to outer surface protein A (OspA) showed that germline IGHV genes encoding anti-OspA antibodies showed higher sequence similarity to their corresponding germline IGHV genes in other Borrelia-susceptible cricetid rodents, suggesting that conserved germline IGHV features are associated with OspA recognition. These findings lay the foundation for further understanding of antibody responses in this important reservoir host.

PMID 42885934
Read full article →
PubMedJournal of clinical medicine2026-10-16

Repeated Relapse-Retreatment Cycles After Omalizumab Withdrawal in Chronic Spontaneous Urticaria: A Real-World Study.

Celik Tuglu Hatice H, Aksu Kurtuluş K

Background/Objectives: Relapse after omalizumab withdrawal is common in chronic spontaneous urticaria (CSU), but patients requiring repeated treatment re-initiation across successive withdrawal cycles remain poorly characterized. This study aimed to characterize patients with repeated relapse requiring omalizumab re-initiation and to determine whether routinely available baseline parameters could distinguish them from other patients with CSU. Methods: This retrospective, single-center study included 46 adults with CSU who achieved disease control with standard-dose omalizumab after an initial 6-month course. Patients were evaluated during a fixed 12-month period following the first withdrawal. Repeated omalizumab re-initiation was defined as relapse requiring re-initiation within 12 weeks after withdrawal on at least two occasions. Baseline clinical and laboratory characteristics were compared between groups, and multivariable logistic regression was performed. Results: Twenty-nine patients (63.0%) met the criteria for repeated omalizumab re-initiation. Baseline disease activity, angioedema, atopic status, autoimmune thyroid disease, previous systemic corticosteroid use, total immunoglobulin E (IgE), anti-thyroid peroxidase antibody (anti-TPO), C-reactive protein (CRP), eosinophil and basophil counts, and inflammatory indices did not differ significantly between the repeated-treatment and comparison groups. Vitamin B12 was the only laboratory parameter showing a significant between-group difference in univariable analysis (259 vs. 335 pg/mL; p = 0.034); however, this association was not retained after multivariable adjustment. None of the variables included in the multivariable model were independently associated with repeated omalizumab re-initiation. Conclusions: Repeated relapse requiring omalizumab re-initiation across successive withdrawal cycles was common during the 12-month observation period. Routinely available baseline clinical and laboratory parameters did not reliably distinguish patients who developed this relapse-retreatment pattern. These findings highlight the difficulty of predicting repeated retreatment requirements from conventional baseline assessments and support further prospective investigation of individualized withdrawal and step-down strategies in patients who develop recurrent relapse-retreatment cycles.

PMID 42882118
Read full article →
PubMedPolymers2026-10-16

Preliminary Synthesis and Basic Performance Characterization of Bio-Based Composite Materials Using Starch and Gelatin as Representative Matrix Phases: Exploratory Conceptual Design for Sustainable Toy Scenarios.

Mao Lijuan L, Gong Yuxin Y, Liu Chenyang C, Li Zhenpeng Z

The overconsumption of traditional plastic products causes serious white pollution and ecological pressure. Bio-based composites derived from natural polymers have emerged as promising sustainable alternatives. This work preliminarily fabricates starch- and gelatin-based composite films modified with natural fillers, and characterizes their basic physicochemical properties, dyeing performance, mechanical behavior, soil burial mass loss, and seed germination responses. On the basis of the tested baseline properties, tentative conceptual design schemes for eco-friendly toys were proposed. Notably, all experimental results in this work are preliminary and limited by insufficient experimental replicates. This study provides only basic experimental data and preliminary feasibility references for developing natural polymer composites for low-carbon consumer product scenarios.

PMID 42885040
Read full article →
PubMedDiagnostics (Basel, Switzerland)2026-10-16

Integrating Anti-SARS-CoV-2 Spike Protein IgG, IL-6, and NK Cell Percentage with Routine Laboratory Markers for COVID-19 Severity Assessment: Development and Validation of the CORIS Nomogram.

Zhang Yihe Y, Xu Xuanming X, Tang Lian L, Ma Jiayue J et al.

Background: Rapid assessment of coronavirus disease 2019 (COVID-19) severity at hospital admission is essential for clinical triage and efficient healthcare resource allocation. However, prediction models developed using data from the early phases of the pandemic may exhibit reduced performance owing to the continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, and existing nomograms rarely integrate routine laboratory parameters with immune-related biomarkers in a systematic manner. Methods: We retrospectively included 774 patients with laboratory-confirmed COVID-19 admitted to Beijing Ditan Hospital between January 2022 and December 2023, and randomly assigned them at a 7:3 ratio to a training set (n = 543) and a validation set (n = 231). Variables consistently selected by three approaches-multivariable logistic regression, least absolute shrinkage and selection operator (LASSO) regression, and recursive feature elimination (RFE)-were defined as core predictors and used to construct the COVID Routine-Immune Score (CORIS) nomogram. Model performance was assessed in terms of discrimination, calibration, and clinical net benefit. The prespecified outcome was non-severe versus severe/critical status determined at hospital admission. CORIS was designed for admission severity discrimination and was not intended to diagnose SARS-CoV-2 infection or predict post-admission deterioration, survival, or thrombotic events. Results: Age, lactate dehydrogenase (LDH), anti-SARS-CoV-2 spike protein immunoglobulin G (IgG), interleukin-6 (IL-6), and NK cell percentage (NK-pct) were consistently identified by all three feature-selection methods. The CORIS nomogram achieved an area under the receiver operating characteristic curve (AUC) of 0.914 (95% CI, 0.884-0.940) in the training set and 0.918 (95% CI, 0.868-0.960) in the validation set, with good calibration (Hosmer-Lemeshow p = 0.322 and 0.659, respectively). In the validation set, the CORIS nomogram significantly outperformed a lymphocyte subset-based model (AUC, 0.811; DeLong p < 0.001) and a routine laboratory parameter-based model (AUC, 0.839; DeLong p = 0.003). Conclusions: The CORIS nomogram integrates predictors spanning four dimensions-demographic susceptibility, tissue injury, systemic inflammation, and immune status-to differentiate non-severe from severe or critical COVID-19. The model demonstrated favorable discrimination and calibration, and may provide an objective and practical tool for severity assessment at hospital admission.

PMID 42882288
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-D immunoglobulin